NEWS & EVENTS

Latest news and upcoming events

05 May 2021

Cytoki Pharma raises $45 million Series A financing

Upcoming events
  • Bioequity 2021
    17 May – 19 May 2021,
    Digital

  • Biospain 2021
    29 September – 1 October 2021,
    Pamplona, Spain

SparingVision to Present at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting

SparingVision has presented three posters highlighting the Company’s recent research into ocular diseases and its lead gene therapy treatment, SPVN06.

Vivet Therapeutics Announces Multiple Projects Update, Including New VTX-803 Preclinical data To Be Presented At 2021 American Society Of Gene And Cell Therapy Annual Meeting

Compelling additional preclinical data further support therapeutic potential of gene therapy product to treat PFIC3.

SparingVision Presents Three Posters at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

SparingVision has presented three posters highlighting the Company’s recent research into ocular diseases and its lead gene therapy treatment, SPVN06.

Cytoki Pharma raises $45 million Series A financing

Ysios Capital joins 38 million euro Series A financing of Cytoki.

Aura Biosciences Presents New Preclinical AU-011 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

AU-011 Demonstrates Targeted Cytotoxicity In Vitro and In Vivo in Both Breast and Lung Tumors.

Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers

Ysios Capital co-leads EUR 51 million Series A financing in Adcendo.

CorWave presents an unprecedented chronic In Vivo Study at the 41st Annual Meeting of the International Society of Heart and Lung Transplantation

This breakthrough is an important step towards the finalization of the development of CorWave's revolutionary technology.

Synendos Therapeutics Expands Series A to CHF 24 million with new investment

Ysios Capital joins existing syndicate of European investors.

SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics

Broadens SparingVision’s innovative genomic medicine pipeline to address both mid and late stages of rod-cone dystrophies with the added potential to combine both products.

Aura Biosciences Announces Publication of Data in Cancer Immunology Research Supporting the Immune Mediated Mechanism of Action of the Virus-Like Drug Conjugate (VDC) Technology Platform

Results Support VDCs induction of Pro Immunogenic Cell Death and the Generation of Long Lasting Adaptive Anti-Tumor Immunity

Newsletter

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.